Insider · CIK 0001247296
D Scott Coward
director
Files at EXAS (EXACT SCIENCES CORP), HUMA (Humacyte, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 6, 2026 | HUMA Humacyte, Inc. | AGrant or award Stock Options (right to buy)derivative | +125,000 | $0.00 | $0 | 125,000 | 5 d ago |
| Jun 12, 2025 | EXAS EXACT SCIENCES CORP | AGrant or award Common Stock | +5,398 | $0.00 | $0 | 57,562 | Jun 16, 2025 |
| Feb 19, 2025 | EXAS EXACT SCIENCES CORP | MOption exercise Common Stock | +2,248 | $0.00 | $0 | 52,831 | Feb 21, 2025 |
| Feb 19, 2025 | EXAS EXACT SCIENCES CORP | FTax withholding Common Stock | -667 | $49.63 | $33k | 52,164 | Feb 21, 2025 |
| Feb 19, 2025 | EXAS EXACT SCIENCES CORP | MOption exercise Restricted Stock Unitsderivative | -2,248 | $0.00 | $0 | 0 | Feb 21, 2025 |
| Jun 13, 2024 | EXAS EXACT SCIENCES CORP | AGrant or award Common Stock | +5,939 | $0.00 | $0 | 50,583 | Dec 20, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.